Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
WX-G250 plus LD-IL-2 provides better outcome in renal cell carcinoma patients
February 8th, 2006
WX-G250 combined with LD-IL-2 could provide an improved clinical outcome in patients with progressive renal cell carcinoma (RCC). "WX-G250 is a chimeric monoclonal antibody that binds to carbonic anhydrase IXG250/MN, which is present on greater than 95% of RCCs of the clear cell subtype. The suggested working mechanism of WX-G250 is by ADCC," scientists writing in the Journal of Urology reported. "Because the number of activated ADCC effector cells can be increased by a low dose interleukin-2 pulsing schedule, a multicenter study was initiated to investigate whether WX-G250 combined with LD-IL-2 could lead to an improved clinical outcome in...
Source: Immunotherapy Weekly (2006-02-08)
|
